Borderline-risk refinement strategy
Borderline-risk refinement strategy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Nov 2, 2026: “Elevated High-Sensitivity C-Reactive Protein as a Prescribing Trigger versus a Risk-Enhancing Factor Identifies Distinct Primary Prevention Populations for Statin Therapy”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on borderline-risk refinement strategy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Despite higher ASCVD event rate in the Borderline-Risk Refinement Strategy group”
- 1 lab in 1 country
- Humans1
What is borderline-risk refinement strategy linked with?
1Studies link borderline-risk refinement strategy with atherosclerotic cardiovascular disease incidence.
Atherosclerotic cardiovascular disease incidence
upin humans1
1 study
Atherosclerotic cardiovascular disease incidence
upin humans1
Borderline-risk refinement strategy is associated with atherosclerotic cardiovascular disease incidence in humans (Compared with the hs-CRP-driven strategy and no statin indication) (9.8% versus 4.4% with the hs-CRP-driven strategy and 2.6% with no statin indication).
“Despite higher ASCVD event rate in the Borderline-Risk Refinement Strategy group”
HumansCompared with the hs-CRP-driven strategy and no statin indication8 yearsn = 2,149
AHA Scientific Sessions 2026 abstract